Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Xbrane Biopharma AB (publ)
  6. News
  7. Summary
    XBRANE   SE0007789409

XBRANE BIOPHARMA AB (PUBL)

(XBRANE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Xbrane Biopharma : enters agreement with AGC Biologics

10/08/2021 | 07:34am EST

Xbrane Biopharma and AGC Biologics, a global Biopharmaceutical CDMO, have entered into an agreement to manufacture Xcimzane, a Cimzia biosimilar candidate, for clinical development.

Under terms of the agreement, the companies will work together to upscale the established Xcimzane manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical trials as well as the Comparability Analytical Assessment required for regulatory filing.

'AGC is a high-quality partner with global manufacturing expertise, and we are pleased to enter into this agreement as the next step in the development of Xcimzane towards clinical trials,' says Martin Amark, CEO Xbrane Biopharma.

Contact:

Mattias Olme

T: +46 8 588 941 51

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
AGC INC. 0.36% 5560 End-of-day quote.54.44%
XBRANE BIOPHARMA AB (PUBL) -2.68% 98.1 Delayed Quote.38.24%
All news about XBRANE BIOPHARMA AB (PUBL)
11/01Xbrane Biopharma releases interim report for January - September 2021
AQ
10/29Invitation to presentation of xbrane biopharma's interim report january - september, 20..
AQ
10/29Interim Report January – September 2021
PU
10/29Xbrane Biopharma releases interim report for January – September 2021
AQ
10/29Xbrane Biopharma AB Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
10/28Invitation to presentation of Xbrane Biopharma's interim report January – Septemb..
AQ
10/27Xbrane announces four more patents granted
AQ
10/18XBRANE BIOPHARMA : presents Nomination Committee
AQ
10/18Xbrane Biopharma Presents Nomination Committee
CI
10/11XBRANE BIOPHARMA : announces two granted patents that strengthens its high yield protein e..
AQ
More news
Financials
Sales 2021 18,7 M 2,06 M 2,06 M
Net income 2021 -225 M -24,8 M -24,8 M
Net cash 2021 445 M 49,0 M 49,0 M
P/E ratio 2021 -10,3x
Yield 2021 -
Capitalization 2 524 M 276 M 278 M
EV / Sales 2021 111x
EV / Sales 2022 8,35x
Nbr of Employees 56
Free-Float 64,5%
Chart XBRANE BIOPHARMA AB (PUBL)
Duration : Period :
Xbrane Biopharma AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends XBRANE BIOPHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 100,80 SEK
Average target price 206,00 SEK
Spread / Average Target 104%
EPS Revisions
Managers and Directors
Martin ┼mark Chief Executive Officer
Anette Lindqvist Chief Financial Officer & Head-Investor Relations
Anders Lennart Tullgren Chairman
David Vikstr÷m Chief Technology Officer
Siavash Bashiri Chief Operating Officer & Head-Biosimilars
Sector and Competitors
1st jan.Capi. (M$)
XBRANE BIOPHARMA AB (PUBL)38.24%276
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-42.48%24 298